Kala Bio Files ATM Offering Of Up To $250M In Common Stock
KALA BIO Inc KALA
$0.76
▲ +3.59%
(+$0.03)
⬆️ Above Yest. High
🗓️ Earnings Next Week
Open
$0.73
Prev Close
$0.73
Day Range
$0.67 – $0.79
52W Range
$0.59 – $1,030.00
Market Cap
$14.62M
Beta
-2.44
EPS (TTM)
$-136.77
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-07-20 |
| Shares Out. | 19,340,000 |
| Website | kalarx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 6 |
| Net Income | -$1.6M |
| Free Cash Flow | -$26.1M |
| Total Assets | $12.3M |
| Total Liabilities | $1.6M |
| Equity | $10.8M |
About KALA BIO Inc
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
KALA BIO Inc is a publicly traded company under the ticker symbol KALA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-07-01)